CMS proposes new prior authorization rules for prescription drugs
CMS has proposed new rules that would extend prior-authorization interoperability requirements to prescription drugs. The plan would not end prior authorization, but it could make requests more electronic, more standardized, and faster to answer for some health plans.
CMS has proposed a new rule that would extend prior-authorization interoperability requirements to prescription drugs. For many patients, the practical takeaway is simple: prior authorization would still exist, but the process could become more electronic, more standardized, and faster in some health plans.
The proposal is not final yet. CMS says it is aiming for a more transparent and reliable process, with clearer data exchange, shorter decision timeframes, and more specific denial information for certain drug requests.
What CMS is proposing
In plain language, the agency wants plans and other affected payers to handle more drug prior authorizations through electronic systems. CMS says that could help providers submit documentation more efficiently, let plans process requests faster, and make coverage rules easier to check in real time.
The proposal also includes updated health IT standards and new reporting requirements for interoperability APIs. CMS says these changes are meant to improve how patient and coverage information moves between providers and payers.
Who would be affected
CMS says the proposal would apply to Medicare Advantage organizations, state Medicaid fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the federal exchanges. CMS also proposes adding small-group FF-SHOP issuers to the interoperability requirements.
The rule would cover both drugs paid under a medical benefit and, for some payers, drugs covered under a pharmacy benefit. Details can still vary by plan, state, and benefit design.
What would change — and what would not
The proposal would not eliminate prior authorization. Instead, it would try to make the workflow more uniform.
CMS says the changes could mean electronic prior authorization for drugs, shorter decision windows, and clearer reasons when a request is denied. The agency also proposes that some payers give a specific denial reason for drug requests, which could help providers resubmit or appeal.
CMS had already finalized prior-authorization and interoperability rules in 2024 for non-drug items and services. The new proposal builds on that framework and extends similar ideas to prescription drugs.
Why it matters for patients
Prior authorization can delay access to treatment when a medication needs insurer approval before it is covered. CMS says its goal is to reduce those delays and cut administrative burden.
The issue is not rare. KFF reported that Medicare Advantage insurers made nearly 53 million prior-authorization determinations in 2024, showing how common the process is for people in managed plans.
What happens next
This is still a proposed rule. CMS will review public comments before deciding whether to finalize the policy. If finalized, CMS says many of the drug-related requirements would begin on October 1, 2027, with some compliance timelines varying by payer type.
CMS also highlighted the proposal in an April 2026 MLN Connects update and webinar, signaling that the agency wants providers, payers, and patients to understand how the changes would work in practice.
What readers can do
If you take a medication that might need prior authorization, watch for notices from your plan and keep copies of prescriptions, chart notes, and approval or denial letters. If a drug is delayed or denied, ask the plan or your prescriber about the appeal process and whether an expedited review is available.
For people on Medicaid, CHIP, Medicare Advantage, or ACA Marketplace plans, the exact rules and timelines can differ. If you are unsure what your plan requires, the member services line and your pharmacy or prescriber’s office are good first stops.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
